Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares iBoxx $ High Yield Corporate Bond ETF (HYG) vs Viatris Inc (VTRS) Price & Performance

iShares iBoxx $ High Yield Corporate Bond ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

iShares iBoxx $ High Yield Corporate Bond ETF vs Viatris Inc — how do they compare? iShares iBoxx $ High Yield Corporate Bond ETF trades at $77.23 (market cap $17.89B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: iShares iBoxx $ High Yield Corporate Bond ETF and Viatris Inc are close in size by market cap, and Viatris Inc pays a 2.75% dividend while iShares iBoxx $ High Yield Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ High Yield Corporate Bond ETF for 60 Days and Viatris Inc for 57 Days on average.

HYGVTRS
Market Cap
$17.89B$20.03B
Volume
44,866,59214,109,977
Sector
Fixed IncomeHealth
52-Week High
$81.28$18.27
52-Week Low
$76.90$9.74
Typical Hold Time
60 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares iBoxx $ High Yield Corporate Bond ETF

HYG trades at $77.205, showing minimal daily movement with a 0.03% gain. Technical indicators signal a bearish trend with moving averages and ADX pointing downward, though RSI suggests potential oversold conditions. The ETF maintains regular dividend distributions, with recent payouts ranging from $0.38 to $0.44. Market focus remains on high-yield bond performance amid rising Treasury yields and Federal Reserve policy uncertainty.

The outlook for HYG remains challenged by persistent bond market volatility and rising interest rates. While the fund's consistent dividend payments provide income support, the bearish technical setup and macroeconomic headwinds suggest continued pressure on high-yield corporate bonds. Investors face risks from credit quality deterioration and duration exposure in a rising rate environment.

Viatris Inc

Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.

The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HYG

No sentiment data available yet.

VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About iShares iBoxx $ High Yield Corporate Bond ETF

HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.

Read more on HYG →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →